Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Abstract: Emulsions of high viscosity silicones are prepared by emulsifying a lower viscosity condensable silicone with a partial phosphate ester surfactant, and ripening the emulsion to obtain a higher viscosity silicone dispersed phase without generation of objectional amounts of octaorganocyclotetrasiloxanes. The emulsions are well suited for body care products.

Abstract: The present invention relates to anhydrous solutions of MX3-Z LiA in a solvent, wherein M is a lanthanide including lanthanum, or yttrium or indium; z>0; and X and A are independently or both monovalent anions, preferably Cl, Br or I. The solution is readily prepared by dissolving or suspending MX3 or its hydrate and z equiv LiA in water or hydrophilic solvents, or mixtures thereof, removing the solvent under vacuum and dissolving the resulting powder in another solvent. The solution of MX3-Z LiA can advantageously be used e.g. in addition reactions of Grignard reagents to ketones and imines. Even the catalytic use of MX3-Z LiA is possible.

Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

Abstract: The present invention provides antiviral compositions that comprise one or more of an ionic multivalent metal component, a cationic polymer, and a cationic surfactant. The present invention also provides methods for making and using such antiviral compositions.

Abstract: A pharmaceutical preparation comprising: a) a core with an active ingredient and with an organic acid and/or the salt of an organic acid; and b) a coating which envelops the core and which comprises a polymer content of (meth)acrylate copolymers which have not more than 15% by weight of cationic or anionic groups, and which comprises at least 60% by weight of a (meth)acrylate copolymer which is composed of free-radically polymerized units of 93 to 98% by weight C1- to C4-alkyl esters of acrylic or of methacrylic acid and 7 to 2% by weight (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, wherein the active ingredient has a solubility in water of at least 10 g/l at 20° C. and the coating comprises silicon dioxide particles having an average particle size in the range from 1 to 50 ?m.

Abstract: A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE1 analogue (e.g. misoprostol) in a solid polyurethane hydrogel. The polyurethane is either linear or cross-linked.

Abstract: We describe the medical, dental, and surgical uses of modified poly(alkylene) materials which are fully resorbable after implantation into the body, and compositions formulated with such modified poly(alkylene) materials.

Abstract: A novel metal/ceramic hybrid material in which the void space of the ceramic is filled with metal. The metal may be bonded to the ceramic, for example by formation of a metal oxide. The metal may be introduced into the ceramic as small particles in a suspension then heated to melt the metal, allowing bonding to the ceramic or better filling of the void space. The hybrid material may be used in a variety of applications.

Abstract: An aqueous based functional system contains a stable fluid polymer suspension (FPS) thickening agent of a polysaccharide, polyethylene glycol (PEG), and hydrated thickening silica. The functional systems may be formulations of personal care excluding oral care, household care, oil field servicing fluids, Civil Engineering servicing fluids, paper coatings, construction fluids, ceramic glazes, foods, firefighting retardants, mineral processing, aqueous based coatings, building materials, construction, pharmaceuticals, medical care, paper making process, and paper coating. The FPS provides to the functional system comparable or better rheology and viscosity properties as compared to when using similar thickening agents in dry, solid form. A method of preparing the aqueous based functional system is also provided by adding a sufficient amount of a stable FPS that is compatible with the functional system to the system to thicken the functional system.

Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.

Abstract: The present invention is directed to processes of making flowable hemostatic compositions and devices that include the flowable hemostatic composition disposed therein, where a volume of a biocompatible liquid, a volume of a biocompatible gas, and an amount of solid particles of a biocompatible polymer are mixed together to form a substantially homogenous composition including a discontinuous gas phase and the solid particles substantially homogenously dispersed throughout a continuous liquid phase to form a flowable hemostatic composition, and the composition then transferred into a device suitable for applying the flowable hemostatic composition to a site of a body requiring hemostasis under conditions effective to maintain the substantially homogeneous dispersion of the gas phase and the solid particles throughout the liquid phase, wherein said transfer of said substantially homogenous hemostatic composition is conducted at an angle.

Abstract: The present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a conjugate having a degradable linkage. The conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods for delivering such compositions are also provided.

Abstract: A process is disclosed for preparing microcapsules having a shell thickness of at least 18 nanometers by polymerizing a tetraalkoxysilane at the oil/water interface of an emulsion containing 0.1 to 0.3 weight percent of a cationic surfactant. The microcapsules are useful to prepare encapsulated sunscreens having sufficient robustness to prevent leakage of the encapsulated sunscreen in a formulated composition.

Abstract: A process is disclosed for preparing polynuclear microcapsules by polymerizing an alkoxysilane at the oil/water interface of a multiple phase emulsion to form a suspension of polynuclear microcapsules. Also disclosed are polynuclear micro-capsules optionally comprising a hydrophilic active and uses thereof.

Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

Abstract: Tissue adhesives formed by reacting an oxidized polysaccharide with a water-dispersible multi-arm polyether amine, wherein at least three of the arms are terminated by primary amine groups, are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; anti-adhesive applications; and as a bulking agent to treat urinary incontinence are described.

Abstract: The present invention relates to a series of dimethicone esters that contain benzyl groups. These esters have a dry feel and are well suited to a variety of uses especially cosmetic uses where they fond use in sunscreen compositions, pigment dispersions, and creams and lotions.

Abstract: It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated.

Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.